ArticleHepatology communications2019
Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis.
Article in Hepatology communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Heterogeneous associations of regional adipose depots with liver fibrosis in U.S. adults.Metabolism open · 2026Article
- The liver-muscle axis in metabolic dysfunction-associated steatotic liver disease: a narrative review and conceptual framework for body-composition phenotyping.Frontiers in medicine · 2026Review
- Association between weight-adjusted waist index and hepatic steatosis and fibrosis: Analyses of the NHANES 2017 to 2020.Medicine · 2025Article
- A Male Japanese Patient with Temple Syndrome Complicated by Type 2 Diabetes Mellitus.Internal medicine (Tokyo, Japan) · 2025Article
- Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort.Journal of hepatology · 2024Article
- Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes.Obesity science & practice · 2024Article
- Association of the fat mass index with hepatic steatosis and fibrosis: evidence from NHANES 2017-2018.Scientific reports · 2024Article
- Skeletal Muscle Consequences of Phosphatidylethanolamine Synthesis Deficiency.Function (Oxford, England) · 2023Article
- NAFLD in normal weight individuals.Diabetology & metabolic syndrome · 2022Review
- A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients.JHEP reports : innovation in hepatology · 2021Article
- Rationale of adding muscle volume to muscle fat infiltration in the definition of an adverse muscle composition is unclear.JHEP reports : innovation in hepatology · 2021Article
- Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients.Scientific reports · 2021Article
- Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.Alimentary pharmacology & therapeutics · 2020Review
- NAFLD in women: Unique pathways, biomarkers and therapeutic opportunities.Current hepatology reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Up to 25% of patients with nonalcoholic fatty liver disease (NAFLD) are not obese but may have a fat or muscle composition that predisposes them to NAFLD. Our aim was to determine whether body composition parameters associate with NAFLD and to identify genetic contributors to this association. This study included two cohorts. The first included 2,249 participants from the Framingham Heart Study who underwent a computed tomography scan to evaluate hepatic steatosis, dual-energy x-ray absorptiometry testing to assess body composition, and clinical examination. Body composition parameters were normalized to total body weight. A subset of participants underwent genotyping with an Affymetrix 550K single-nucleotide polymorphism array. The second cohort, Michigan Genomics Initiative, included 19,239 individuals with genotyping on the Illumina HumanCoreExome v.12.1 array and full electronic health record data. Using sex-stratified multivariable linear regression, greater central body fat associated with increased hepatic steatosis while greater lower extremity body fat associated with decreased hepatic steatosis. Greater appendicular lean mass was associated with decreased hepatic steatosis in men but not in women. A polygenic risk score for lipodystrophy (regional or global loss of adipose tissue) was associated with increased hepatic steatosis, increased liver fibrosis, and decreased lower extremity fat mass.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.